{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Oral+Placebo&page=7", "query": { "intervention": "Matching Oral Placebo", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 3455, "total_pages": 346, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Oral+Placebo&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Oral+Placebo&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T05:48:01.536Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04206553", "title": "A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Bullous Pemphigoid" ], "interventions": [ { "name": "dupilumab", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" }, { "name": "Oral corticosteroids (OCS)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 106, "start_date": "2020-10-28", "completion_date": "2025-01-05", "has_results": true, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-14T05:48:01.536Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Redwood City, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Redwood City", "state": "California" }, { "city": "Farmington", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04206553" }, { "nct_id": "NCT04508023", "title": "A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Coronavirus Disease 2019 (COVID-19)" ], "interventions": [ { "name": "Rivaroxaban", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Standard of Care (SOC)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1284, "start_date": "2020-08-13", "completion_date": "2022-06-01", "has_results": true, "last_update_posted_date": "2023-07-18", "last_synced_at": "2026-10-14T05:48:01.536Z", "location_count": 17, "location_summary": "Tucson, Arizona • Los Angeles, California • Oakland, California + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04508023" }, { "nct_id": "NCT00370331", "title": "RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Purpura, Thrombocytopaenic, Idiopathic" ], "interventions": [ { "name": "eltrombopag", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 197, "start_date": "2006-11", "completion_date": "2008-07", "has_results": true, "last_update_posted_date": "2017-04-18", "last_synced_at": "2026-10-14T05:48:01.536Z", "location_count": 26, "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 20 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00370331" }, { "nct_id": "NCT04492722", "title": "A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Kidney Disease" ], "interventions": [ { "name": "AZD5718", "type": "DRUG" }, { "name": "Dapagliflozin 10 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 613, "start_date": "2020-10-01", "completion_date": "2022-09-06", "has_results": true, "last_update_posted_date": "2024-12-20", "last_synced_at": "2026-10-14T05:48:01.536Z", "location_count": 22, "location_summary": "Canoga Park, California • La Mesa, California • San Carlos, California + 19 more", "locations": [ { "city": "Canoga Park", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "San Carlos", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Victorville", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04492722" }, { "nct_id": "NCT05480072", "title": "Endocannabinoids, Stress, Craving And Pain Effects Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Opioid Use Disorder" ], "interventions": [ { "name": "Palmitoylethanolamide", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 12, "start_date": "2022-11-01", "completion_date": "2025-01-14", "has_results": false, "last_update_posted_date": "2025-10-20", "last_synced_at": "2026-10-14T05:48:01.536Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05480072" }, { "nct_id": "NCT06630286", "title": "Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "ISL/LEN", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" }, { "name": "PTM B/F/TAF", "type": "DRUG" }, { "name": "PTM ISL/LEN", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 609, "start_date": "2024-10-09", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-10-14T05:48:01.536Z", "location_count": 60, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 50 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06630286" }, { "nct_id": "NCT06961266", "title": "A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Narcolepsy" ], "interventions": [ { "name": "JZP441", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 6, "start_date": "2025-05-13", "completion_date": "2026-01-29", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-10-14T05:48:01.536Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Cincinnati, Ohio • Columbia, South Carolina + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbia", "state": "South Carolina" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06961266" }, { "nct_id": "NCT01011829", "title": "Varenicline vs Placebo for the Treatment of Methamphetamine Dependence", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Methamphetamine Dependence", "Substance Abuse", "Methamphetamine Abuse" ], "interventions": [ { "name": "Varenicline", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2009-11", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2013-03-14", "last_synced_at": "2026-10-14T05:48:01.536Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01011829" }, { "nct_id": "NCT02997202", "title": "A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "gilteritinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 356, "start_date": "2017-08-16", "completion_date": "2023-05-09", "has_results": true, "last_update_posted_date": "2025-01-17", "last_synced_at": "2026-10-14T05:48:01.536Z", "location_count": 46, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 35 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02997202" }, { "nct_id": "NCT03661983", "title": "Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Tourette's Disorder (TD)" ], "interventions": [ { "name": "Aripiprazole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 36, "start_date": "2018-10-13", "completion_date": "2020-06-30", "has_results": true, "last_update_posted_date": "2021-03-09", "last_synced_at": "2026-10-14T05:48:01.536Z", "location_count": 38, "location_summary": "Anaheim, California • Riverside, California • Santa Ana, California + 30 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03661983" } ] }